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6)
Although AF is generally not as immediately life-threatening as ventricular arrhythmias, patients with AF have increased risks of stroke and heart failure, and reduced quality of life. [7] [8] [9] AF leads to a 5-fold increased risk of stroke, and it is estimated that up to 25% of all strokes in the elderly are a consequence of AF. 6) Furthermore, AFrelated strokes are more severe, with patients twice as likely to be bedridden as patients with stroke from other etiologies and more likely to die.
10-12)
The mean rate of ischemic stroke among patients with nonvalvular AF is 5% per year, which is 2-7 times that of the general adult population.
9) The risk of stroke increases from 1.5% in patients with AF aged 50-59 years to 23% in those aged 80-89 years. 11) Antithrombotic therapy, particularly with warfarin, decreases the risk of stroke in patients with AF.
13)14)
Warfarin use is associated with a 64% risk reduction in stroke and a 26% reduction in all cause mortality, compared with control or placebo, while aspirin is associated with a non-significant 19% risk reduction, with no impact on mortality.
15)
Although AF increases the risk of stroke and thromboembolism 5-fold, this risk is not homogeneous and is altered by the presence of various stroke risk factors. Thus, risk stratification is important to identify patients with a stroke risk that is significant enough to justify the bleeding risk associated with OACs.
CHADS 2 Score
The CHADS2 score 16) is the most commonly used risk score for stroke in AF patients. Despite its common use, several concerns have remained. First, recent studies have not confirmed that the CHADS2 score has good predictive value for 'high risk' individuals. 17) Second, several known common risk factors for stroke in AF, particularly an age of 65-74 years, female sex, and vascular disease, are not accounted for in the CHADS2 score. 18)19) Third, aspirin is recommended for a CHADS2 score of 0, and OACs are recommended for a CHADS2 score ≥2, but either aspirin or OAC is considered appropriate for patients with a CHADS2 score of 1. Several cohorts have shown that 30-50% of AF patients have a CHADS2 score of 1, implying that a large number of AF patients have no clear recommendation for anticoagulation based on these criteria. shown that even those with a CHADS2 score of 0 can have an annual stroke rate as high as 3.2% (which is not 'low risk') and those with a score of 1 can have an annual stroke rate of 8%. 22) Furthermore, the CHADS2 score is inadequate to predict the absence of thromboembolism in a cohort of AF patients without any risk factors followed up for 12 years.
23)
Given the limitations of relying only on the five risk factors in the CHADS2 score, recent guidelines have introduced modifications so as not to rely only on CHADS2. The 2012 American College of Chest Physicians guidelines recommend initially using the CHADS2 score, but, where the CHADS2 score=0, additional non-CHADS2 risk factors such age 65-74 years, vascular disease and female gender should be taken into consideration. 24) A similar approach has been suggested in the Canadian Cardiovascular Society 25) and the Japanese Circulation Society guidelines.
26)

CHA 2 DS 2 -VASc Score
Real-world cohort data have provided further information to inform stroke risk. Indeed, the independent predictive values of female sex, age 65-74 years, and vascular disease are now evident from numerous cohorts.
27)28) In addition, a history of congestive heart failure (the C in CHADS2) has not proven to be a consistent stroke risk factor, 29) whereas moderate-to-severe systolic impairment is clearly an independent stroke risk factor. 30) Thus, the European Society of Cardiology (ESC) guidelines now recommend the use of the CHA2DS2-VASc score for stroke risk stratification (Table 1 and 2). The most recent guidelines of the Asia Pacific Heart Rhythm Society, 31) American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS), 32) and the United Kingdom National Institute for Health and Care Excellence (NICE) all recommend use of the CHA2DS2-VASc score for stroke risk stratification. In its original validation, the CHA2DS2-VASc score was compared with seven other contemporary stroke risk stratification schemas for 1084 patients in the Euro Heart Survey on AF. The survey data demonstrated reasonable predictive ability for high-risk patients and was good at identifying low-risk patients and categorizing few patients into the moderate-risk category. The CHA2DS2-VASc score has subsequently been validated in numerous AF populations, most commonly compared with CHADS2. 33) All studies have consistently confirmed the ability of the CHA2DS2-VASc score to reliably identify truly low-risk patients, who can be managed with no antithrombotic therapy, as well as to predict stroke and thromboembolism in high-risk patients with AF. Indeed, patients with <65 years of age (irrespective of gender) have a very low absolute stroke risk, and a CHA2DS2-VASc score of 0 (in males) and 1 (in females) identifies these low risk patients as the first decision step, 23)34)35) who may reasonably be considered for no antithrombotic treatment. Subsequent to this step, all other AF patients with one or more stroke risk factors (that is CHA2DS2-VASc score=1 in males, or score ≥2 in all), should be considered for OAC (Fig. 1) . Despite the strong evidence in favor of OAC use for stroke prevention, a recent systematic review 36) investigating the current treatment practice for stroke prevention in eligible AF patients revealed the underuse of OACs as treatment (defined as <70% of eligible patients receiving OAC), particularly among those patients at highest risk (i.e., those with a previous stroke/transient ischemic attack). Overestimation of the risk of bleeding by physicians is a key barrier to OAC prescription 37) particularly among elderly patients. In the the Birmingham Atrial Fibrillation Treatment of the Aged Study trial, OACs were beneficial in the elderly with a superior reduction in stroke and thromboembolism. Importantly, there was no significant difference in major bleeding between warfarin and aspirin.
38)
Who Is at Risk for Bleeding?
Bleeding risk assessment is complex, and many risk factors for bleeding are also risk factors for stroke. Many risk factors for bleeding have been identified. As recently as 2008, only four bleeding risk scores had been applied to AF populations, and only one score, Hepatic or renal disease, Ethanol abuse, Malignancy, Older age, Reduced platelet count or function, Re-bleeding, Hypertension, Anemia, Genetic factors, Excessive fall risk, and Stroke (HEMORR2HAGES) had been derived and validated in an AF population.
39)
In 2010, the HAS-BLED score ( Fig. 2 ) was first proposed, having been derived and validated in the Euro Heart survey population.
40)
HAS-BLED score is a simple bleeding risk tool representing each of the following common bleeding risk factors and assigning 1 point for the presence of each: hypertension (uncontrolled systolic blood pressure >160 mm Hg), abnormal renal and/or liver function, previous stroke, bleeding history or predisposition, labile INRs, elderly, and concomitant drugs and/or alcohol excess. The HAS-BLED scores range from 0-9, with scores ≥3 indicating high risk of bleeding, for which caution and regular review of the patient are recommended. The HAS-BLED score has been validated in multiple independent populations, where it performed as well as (and sometimes better than) the more complex HEMORR2HAGES score. 40)41) A close correlation also exists between an increasing HAS-BLED score and major bleeding or intracranial hemorrhage. 27) In one analysis of AF patients receiving anticoagulants, the HAS-BLED score was a good predictor of major bleeding and a modest predictor of cardiovascular events and death.
42)
In 2011, the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) bleeding risk score in AF patients receiving anticoagulants was proposed. 43) Five independent variables were included in the final model: anemia (hemoglobin <13 g/dL in men and <12 g/dL in women; 3 points), severe renal disease (glomerular filtration rate <30 mL/min or dialysis dependent; 3 points), age ≥75 years (2 points), prior bleeding (1 point), and hypertension (1 point). Collapsed into a 3-category risk score, major bleeding rates were 0.8% for low-risk (0-3 points), 2.6% for intermediate-risk (4 points) and 5.8% for high-risk (≥5) patients. The high-risk category effectively concentrated bleeding events such that 42% of events occurred in 10.2% HAS-BLED score has been shown to outperform the older HEM-ORR2HAGES and less practical ATRIA scores in predicting clinically relevant bleeding in multiple real-world and trial cohorts. [44] [45] [46] Thus, the HAS-BLED score is recommended in the ESC guidelines as well as the Canadian Cardiovascular Society guidelines 25) and the 2014 NICE guidelines. The AHA/ACC/HRS guidelines and the JCS guidelines 2014 have also introduced the specific contents of the HAS-BLED score and implied the importance of the score. In the ESC guidelines, a HAS-BLED score ≥3 represents sufficient high risk, such that caution and/or regular review of a patient is needed to minimize the risk of complications. It also encourages identification of correctable common bleeding risk factors, such as uncontrolled blood pressure, labile INRs (if on warfarin, to improve time in the therapeutic range), and concomitant aspirin or NSAID use. The determination of such a score allows informed decisions regarding the use of a low-dose or high-dose regime of non-VKA OACs (NOACs, previously referred to as new or novel OACs).
47) Importantly, a high HAS-BLED should not be a reason to withhold OAC as the net clinical benefit for stroke reduction outweighs the small risk of serious bleeding, but rather to identify those patients in whom caution with such treatment and regular reviews are warranted.
Non-Vitamin K Oral Anticoagulants
Large scale phase 3 clinical trials have demonstrated efficacy, safety, and convenience of the NOACs as compared to dose-adjusted warfarin (Table 3) . [48] [49] [50] [51] The NOACs occur in two main drug classes:
oral direct thrombin inhibitors (e.g., dabigatran) and oral Factor Xa inhibitors (e.g., rivaroxaban, apixaban, edoxaban). All these agents have shown non-inferiority to warfarin therapy, and in some cases, superior efficacy for the primary endpoints of stroke and systemic embolism (dabigatran 150 mg b.i.d. or apixaban) or ischemic stroke (dabigatran 150 mg b.i.d.). Importantly, all the NOACs significantly reduce the risk of hemorrhagic stroke and intracranial hemorrhage compared with warfarin. 52) Although all-cause mortality was significantly reduced with apixaban and edoxaban 30 mg, a similar trend was also observed in other studies. Current guidelines recommend that NOACs are preferable to Vitamin K antagonist (VKA) therapy in the vast majority of patients with nonvalvular AF. 1)25) However, no head-to-head trials have been performed, and indirect comparison analyses do not suggest profound differences in efficacy endpoints among the NOACs. Therefore, it is difficult to provide definitive recommendations regarding which NOACs should be used in which patients. Moreover, high quality anticoagulation control with VKAs is associated with good efficacy and safety with low stroke and bleeding risks. Thus, effective stroke prevention in various guidelines with OACs refers to the use of well-controlled warfarin { time in therapeutic range (TTR) ≥70%} or NOAC.
1)
While NOACs generally offer many advantages, a clinical dilemma is the prediction of which newly diagnosed non-anticoagulated AF patients would do well on warfarin, with a high TTR. This is especially relevant considering the costs of the NOACs and given that the benefits of NOACs over VKAs may be only marginal in those with high TTRs. An ESC position paper 53) recommended the use of a simple new SAMe-TT22R2 { Sex female, Age <60 years, Medical history (more than two comorbidities), Treatment (interacting drugs), Tobacco use (doubled), Race (doubled) } score incorporating common clinical factors. [54] [55] [56] [57] This score aids decision-making by identifying those AF patients likely to do well on warfarin (SAMe-TT2R2score 0-1) or those more likely to have poor anticoagulation control (SAMeTT2R2score >2). Patients with a SAMe-TT2R2score >2 would probably be better treated with NOACs as initial therapy or targeted to improve their anticoagulation control if warfarin is used. Indeed, poor anticoagulation control in the initial period following warfarin initiation may lead to an excess of strokes pending stabilization of INR control.
58)
Balancing Stroke and Bleeding Risk
On the most simplistic level, the risk of ischemic stroke, which OACs have been attempting to prevent, can be balanced with the risk of the most serious bleeding complication of intracranial hemorrhage.
3) A net clinical benefit analysis 59) showed that the only category of AF patients with a negative net clinical benefit after warfarin therapy were those with a CHA2DS2-VASc score of 0, reflecting the "truly low-risk" status of such patients. Patients with a high HAS-BLED score (≥3) derived an even higher net clinical benefit given that their absolute gain in ischemic stroke reduction far outweighed the small increase in intracranial bleeding. Broadly similar findings were observed by Friberg et al. 60) who concluded that warfarin should perhaps be more widely used in AF patients given that the net clinical benefit was in favor of its use in most patients, again with the exception of those with a CHA2DS2-VASc score of 0. Siu et al. 61) found a similarly positive net clinical benefit for warfarin over aspirin, and warfarin over no therapy, in Chinese AF patients with one or more additional stroke risk factors. Novel oral anticoagulants may provide an even greater net clinical benefit. In a modeling analysis, Banerjee et al. 62) showed that in patients with a CHA2DS2-VASc score of 1, apixaban and both doses of dabigatran (150 and 110 mg twice daily) had a positive net clinical benefit. All three NOACs (dabigatran, rivaroxaban, and apixaban) appear to offer superior net clinical benefit over warfarin in patients with a CHA2DS2-VASc score ≥2, regardless of bleeding risk. When the risks of both stroke and bleeding are elevated, dabigatran, rivaroxaban, and apixaban appear to have an even greater net clinical benefit than warfarin. 
Atrial Fibrillation in the Asian Population
Both bleeding and thromboembolism rates are generally higher in Asians than non-Asians because of difficulty in proper usage of warfarin in Asians. In a population-based study, Asians had a 2-fold increase in the risk of intracerebral hemorrhage compared to white people. 63) Moreover, the risk of intracranial hemorrhage increased to 4-fold compared to white people despite a similar intensity of anticoagulation.
64)
On the other hand, the risk of stroke and systemic embolism for AF patients taking warfarin appears to be higher in Asians than nonAsians. When Asian and non-Asian patients on warfarin were compared in the RE-LY trial, 51)65) Asian patients had a higher stroke rate compared to non-Asians (3.06% vs. 1.48%), as well as a poorer average TTR (55%), reflecting poorer quality of anticoagulation control in these patients. In the ROCKET AF trial, 48) the risk of stroke and systemic embolism was also higher (3.4% vs. 2.4%) in East Asians despite the mean CHADS2 score being lower (3.2 vs. 3.47). In the ARIS-TOTLE trial, 49)66) the risk of stroke and systemic embolism was also higher in Asians (3.39% vs. 1.38%). Overall, Asian physicians tended to keep INR level in a lower range for patients on warfarin due to higher risk of bleeding than non-Asians. On the basis of these trials, NOACs are preferentially indicated in Asians in terms of both efficacy and safety. Also, some preliminary data suggest that Asian patients with AF might not be the same.
67)
Thus, future prospective studies are needed for the proper use of NOACs in reference to different ethnic backgrounds.
Non-Pharmacological Approaches
New devices and systemic therapies have been developed for stroke prevention and are being testing or have been approved for use. In particular, mechanical interventions for stroke prevention have emerged and are being rapidly used. For example, left atrial appendage (LAA) occlusive devices are an alternative treatment strategy for preventing blood clot formation in patients with AF. For patients with AF who are have an ongoing serious bleeding history and/ or are noncompliant (which can be a significant issue for those on warfarin), the possibility of LAA occlusion being an alternative to OACs can be considered.
Several occlusion devices have been developed to exclude the LAA from the systemic circulation, i.e., the Percutaneous Left Atrial Appendage Transcatheter Occlusion (PLAATO; ev3, Plymouth, MN, USA), WATCHMAN (Atritech, Plymouth, MN, USA), and Amplatzer Cardiac Plug devices (AGA Medical, Plymouth, MN, USA). However, the clinical development program for the PLAATO device has been halted, as the device was rather rigid and required up to 50% oversizing compared with the LAA orifice to achieve a stable position at implantation.
68)
The WATCHMAN device has been evaluated in a prospective, randomized non-inferiority clinical trial (PROTECT-AF) that compared percutaneous LAA closure and subsequent discontinuation of warfarin with long-term, dose-adjusted warfarin treatment in patients with nonvalvular AF and at least one risk factor for stroke.
69) The WATCHMAN device was non-inferior to warfarin with regard to the primary efficacy endpoints-occurrence of ischemic or hemorrhagic stroke, systemic embolism, and cardiovascular death (RR=0.71; 95% CI 0.44-1.30). However, more primary safety events (excessive major bleeding or procedure-related complications, such as serious pericardial effusion, device embolization, and procedure-related stroke) occurred in the WATCHMAN group (RR=1.53; 95% CI 0.95-2.70).
70)
More recently, the ASA Plavix Feasibility Study With WATCHMAN Left Atrial Appendage Closure Technology (ASAP study) reported that LAA closure with the WATCHMAN device can be safely performed without a warfarin transition and is a reasonable alternative in patients at high risk for stroke but with contraindications to systemic OACs.
71)
Overall, the available data suggest that LAA occlusion reduces the risk of AF-related stroke and might be a promising option, at least for selected patients with AF ineligible for OACs or those who experience severe bleeding complications during treatment with OACs. On the basis of the data available (mostly the PROTECT-AF trial), LAA closure has been given a class IIb recommendation in the 2012 focused update of the ESC AF guidelines.
Quo Vadis?
Despite the impressive performance of NOACs, some uncertainties exist regarding the new drugs, and more information is needed concerning the long-term anticoagulation with these agents. Also, LAA occlusion reduces the risk of AF-related stroke and might be a promising option, at least for high-risk patients with AF ineligible for OAC or those who experience severe bleeding complications during treatment with OACs. However, LAA occlusion needs to be performed with care by experienced operators because periprocedural complications, such as pericardial effusion or stroke, have been documented. With increased operator experience and technical improvements in LAA occlusion devices, complications can be minimized.
Conclusion
Decisions regarding appropriate stroke prevention require individual assessment of stroke and bleeding risk on anticoagulation with VKA therapy and NOACs. Use of risk scores such as CHA2DS2-VASc and HAS-BLED can help in the selection of appropriate antithrombotic agents and management strategies. Also, availability of NOACs offers new possibilities, and these drugs have changed the landscape for stroke prevention in AF.
